{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:32:05Z","timestamp":1786375925475,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10928-026-10038-7","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:58:13Z","timestamp":1780599493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial"],"prefix":"10.1007","volume":"53","author":[{"given":"Yibo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hadigol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Ruberio","family":"Lincha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Zohren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"DeAnnuntis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane D.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"1","key":"10038_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/OP.21.00206","volume":"18","author":"N Sayegh","year":"2022","unstructured":"Sayegh N, Swami U, Agarwal N (2022) Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract 18(1):45\u201355","journal-title":"JCO Oncol Pract"},{"key":"10038_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","volume":"116","author":"HJ Boyle","year":"2019","unstructured":"Boyle HJ, Alibhai S, Decoster L et al (2019) Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 116:116\u2013136","journal-title":"Eur J Cancer"},{"issue":"1","key":"10038_CR3","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"key":"10038_CR4","doi-asserted-by":"crossref","unstructured":"Abida W, Armenia J, Gopalan A et al (2017) Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol","DOI":"10.1200\/PO.17.00029"},{"key":"10038_CR5","doi-asserted-by":"crossref","unstructured":"Chung JH, Dewal N, Sokol E et al (2019) Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol 3:PO.18.00283","DOI":"10.1200\/PO.18.00283"},{"issue":"22","key":"10038_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"issue":"8","key":"10038_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN et al (2023) Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer. N Engl J Med 388(8):719\u2013732","journal-title":"N Engl J Med"},{"key":"10038_CR8","doi-asserted-by":"crossref","unstructured":"Rao A, Moka N, Hamstra DA, Ryan CJ (2022) Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now? Cancers (Basel) 14(3):801","DOI":"10.3390\/cancers14030801"},{"issue":"11","key":"10038_CR9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn WR, Parker JS, Lee MX et al (2013) Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3(11):1245\u20131253","journal-title":"Cancer Discov"},{"issue":"29","key":"10038_CR10","doi-asserted-by":"publisher","first-page":"14573","DOI":"10.1073\/pnas.1908547116","volume":"116","author":"B Gui","year":"2019","unstructured":"Gui B, Gui F, Takai T et al (2019) Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc Natl Acad Sci U S A 116(29):14573\u201314582","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10038_CR11","doi-asserted-by":"publisher","first-page":"113249","DOI":"10.1016\/j.ejca.2023.113249","volume":"192","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Zhang T, Efstathiou E et al (2023) The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer 192:113249","journal-title":"Eur J Cancer"},{"issue":"9","key":"10038_CR12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","volume":"22","author":"JS de Bono","year":"2021","unstructured":"de Bono JS, Mehra N, Scagliotti GV et al (2021) Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol 22(9):1250\u20131264","journal-title":"Lancet Oncol"},{"issue":"4","key":"10038_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2217\/fon-2021-0811","volume":"18","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Azad A, Shore ND et al (2022) Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol 18(4):425\u2013436","journal-title":"Future Oncol"},{"issue":"10398","key":"10038_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J et al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402(10398):291\u2013303","journal-title":"Lancet"},{"key":"10038_CR15","unstructured":"TALZENNA@ [Package Insert] (2024) Drugs@FDA, 02\/06\/ https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/211651s012lbl.pdf"},{"issue":"1","key":"10038_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Azad AA, Matsubara N et al (2024) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 30(1):257\u2013264","journal-title":"Nat Med"},{"issue":"2","key":"10038_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/jcph.1520","volume":"60","author":"Y Yu","year":"2020","unstructured":"Yu Y, Durairaj C, Shi H, Wang DD (2020) Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer. J Clin Pharmacol 60(2):218\u2013228","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10038_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/cts.12540","volume":"11","author":"Y Ji","year":"2018","unstructured":"Ji Y, Jin JY, Hyman DM, Kim G, Suri A (2018) Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology. Clin Transl Sci 11(4):345\u2013351","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10038_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/psp4.12196","volume":"6","author":"FT Musuamba","year":"2017","unstructured":"Musuamba FT, Manolis E, Holford N et al (2017) Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA\/EFPIA Workshop on Dose Finding (London 4\u20135 December 2014). CPT Pharmacometrics Syst Pharmacol 6(7):418\u2013429","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"10038_CR20","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/jcph.1626","volume":"60","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy M, Yu Y, Litton JK et al (2020) Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1\/2 Mutations in the EMBRACA and ABRAZO Trials. J Clin Pharmacol 60(10):1334\u20131343","journal-title":"J Clin Pharmacol"},{"key":"10038_CR21","doi-asserted-by":"publisher","first-page":"S992","DOI":"10.1016\/j.annonc.2023.09.2782","volume":"34","author":"AA Azad","year":"2023","unstructured":"Azad AA, Hadigol VRLM, Hoffman J, Agarwal N, Matsubara N, Wang Y, DeAnnuntis L, Zohren F, Wang D (2023) Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. Ann Oncol 34:S992\u2013S993","journal-title":"Ann Oncol"},{"issue":"20","key":"10038_CR22","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1016\/j.molcel.2024.09.020","volume":"84","author":"X Lin","year":"2024","unstructured":"Lin X, Gupta D, Vaitsiankova A et al (2024) Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts. Mol Cell 84(20):3916\u20133931e3917","journal-title":"Mol Cell"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10038-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-026-10038-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-026-10038-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:25:55Z","timestamp":1786375555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-026-10038-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10038"],"URL":"https:\/\/doi.org\/10.1007\/s10928-026-10038-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6915587\/v1","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30"}}